These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Deletion of Smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression. Qin G; Wang GZ; Guo DD; Bai RX; Wang M; Du SY J Dig Dis; 2018 May; 19(5):301-313. PubMed ID: 29696816 [TBL] [Abstract][Full Text] [Related]
46. Protectin D1 inhibits TLR4 signaling pathway to alleviate non-alcoholic steatohepatitis via upregulating IRAK-M. Liu H; Li N; Kuang G; Gong X; Wang T; Hu J; Du H; Zhong M; Guo J; Xie Y; Xiang Y; Wu S; Yuan Y; Yin X; Wan J; Li K Free Radic Biol Med; 2024 Jan; 210():42-53. PubMed ID: 37984750 [TBL] [Abstract][Full Text] [Related]
47. Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency. Kim M; Yoo G; Randy A; Kim HS; Nho CW Mol Nutr Food Res; 2017 May; 61(5):. PubMed ID: 27981809 [TBL] [Abstract][Full Text] [Related]
48. Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible? Lytle KA; Jump DB PLoS One; 2016; 11(1):e0146942. PubMed ID: 26761430 [TBL] [Abstract][Full Text] [Related]
49. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204 [TBL] [Abstract][Full Text] [Related]
50. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173 [TBL] [Abstract][Full Text] [Related]
51. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428 [TBL] [Abstract][Full Text] [Related]
53. Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet. Ibusuki R; Uto H; Arima S; Mawatari S; Setoguchi Y; Iwashita Y; Hashimoto S; Maeda T; Tanoue S; Kanmura S; Oketani M; Ido A; Tsubouchi H Liver Int; 2013 Nov; 33(10):1549-56. PubMed ID: 23682724 [TBL] [Abstract][Full Text] [Related]
54. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Loyer X; Paradis V; Hénique C; Vion AC; Colnot N; Guerin CL; Devue C; On S; Scetbun J; Romain M; Paul JL; Rothenberg ME; Marcellin P; Durand F; Bedossa P; Prip-Buus C; Baugé E; Staels B; Boulanger CM; Tedgui A; Rautou PE Gut; 2016 Nov; 65(11):1882-1894. PubMed ID: 26338827 [TBL] [Abstract][Full Text] [Related]
55. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139 [TBL] [Abstract][Full Text] [Related]
56. An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors. Ponnusamy S; Tran QT; Thiyagarajan T; Miller DD; Bridges D; Narayanan R Exp Biol Med (Maywood); 2017 Mar; 242(6):606-616. PubMed ID: 28092182 [TBL] [Abstract][Full Text] [Related]
57. G-Protein-Coupled Receptor 120 Agonist Mitigates Steatotic and Fibrotic Features Triggered in Obese Mice by the Administration of a High-Fat and High-Carbohydrate Diet. Pompili S; Cappariello A; Vetuschi A; Sferra R ACS Omega; 2024 Jul; 9(29):31899-31909. PubMed ID: 39072106 [TBL] [Abstract][Full Text] [Related]
58. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. Hwang S; Yun H; Moon S; Cho YE; Gao B Front Endocrinol (Lausanne); 2021; 12():751802. PubMed ID: 34707573 [TBL] [Abstract][Full Text] [Related]
59. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951 [TBL] [Abstract][Full Text] [Related]
60. GPR120, a potential therapeutic target for experimental colitis in IL-10 deficient mice. Zhao J; Wang H; Shi P; Wang W; Sun Y Oncotarget; 2017 Jan; 8(5):8397-8405. PubMed ID: 28039475 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]